hypertension (PH). 13, 14 Macrophage accumulation and activation promote the release of cytokines, vasoactive molecules, and reactive oxygen species, all of which have been implicated in pulmonary vascular remodeling. 9 Taken together, these results emphasize the vital role of macrophages in PAH development.
In recent years, interest has grown in targeting inflammation (especially macrophages) as a strategy for managing PAH. Macrophage depletion or inactivation has been found to prevent PH in several experimental PH models. 15 Moreover, it is reported that administering granulocyte-macrophage colony stimulating factor to mice could induce severe PH in association with enhanced recruitment of perivascular macrophages and granulocyte-macrophage colony stimulating factor blockade significantly prevented this pathology. 16 Collectively, pulmonary vascular remodeling may be reversed by approaches targeting specific inflammatory processes. However, with an increasing number of targets acting on inflammatory cells in PAH, some approaches may prove ineffective, and, for others, the risk/benefit ratio will likely be unacceptable. For example, antagonizing TGF (transforming growth factor)-β1 can cause complications, such as uncontrolled infection. 17 Therefore, it is necessary and meaningful to explore novel target molecules closely linked to macrophages.
Lgmn (Legumain), also known as asparaginyl endopeptidase, is a newly discovered lysosomal cysteine protease that belongs to the C13 family of cysteine proteases [18] [19] [20] and is mainly expressed in macrophages. 21, 22 Lgmn can promote tumor invasion and metastasis by activating MMP (matrix metalloproteinase)-2. [23] [24] [25] Patients with carotid atherosclerosis reportedly displayed significantly higher plasma Lgmn levels than healthy controls 22, 26 and Lgmn colocalized in macrophages within plaques. In addition, Lgmn activity is sharply increased in the pancreas during acute and chronic pancreatitis, and its expression is localized primarily in macrophages. 27 However, an association between Lgmn and PAH has not been elucidated.
In the present study, we observed that Lgmn generation was markedly upregulated in lung tissues from both PAH mice treated with hypoxia plus SU5416 (HySu), the latter being an inhibitor of the vascular endothelial growth factor receptor, and MCT (monocrotaline)-treated PAH rats. Deletion of Lgmn (either global or specifically in macrophages) attenuated HySu-induced PAH and pulmonary vascular remodeling by suppressing MMP-2/TGF-β1 signaling. More importantly, treatment with an Lgmn inhibitor attenuated the development of PAH in MCT-and HySu-induced PAH animal models. Therefore, our data demonstrated that Lgmn is a potential therapeutic target for the management of PAH.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Population
PH is defined as a resting mean pulmonary artery pressure of ≥25 mm Hg confirmed by right heart catheterization. According to the PH classification of the fifth World Symposium of PH (Nice, France, 2013), idiopathic PAH (iPAH) belongs to the first group characterized by the absence of underlying causative disease. A total of 31 patients with iPAH who received right heart catheterization were enrolled between March 2012 and March 2018, similar to 31 control subjects who were matched in terms of age, sex, and ethnicity. Briefly, iPAH diagnosis was based on pulmonary arterial systolic pressure, as initially identified by echocardiography and subsequently confirmed by right heart catheterization. Considering the multiple functions of Lgmn in various diseases, patients with comorbidities, such as chronic inflammatory diseases, left heart disease, diabetes mellitus, malignancies, and liver and renal insufficiency were excluded. Written informed consent was obtained from all subjects before they participated in this study. All protocols involved the human specimens were approved by the Ethics Committee of Ruijin Hospital (Shanghai Jiaotong University School of Medicine). All experiments conformed to the principles set out in the WMA Declaration of Helsinki and the Department of Health and Human Services Belmont Report.
Animals
Lgmn F/F mice, possessing 2 loxP sites flanking exon 3 of the Lgmn gene (constructed by Shanghai Biomodel Organism Co, Ltd, Shanghai, China), were maintained in a C57BL/6 genetic background. Lgmn −/− mice were generated by crossing Lgmn F/F mice with C57BL/6 DDX4-Cre mice (Shanghai Biomodel Organism Co, Ltd, Shanghai, China). Lgmn F/F mice were crossed with C57BL/6 LysM Cre mice to generate Lgmn
Cre (Mac-Lgmn knockout) mice. All animal used for the experiments were male mice or rats based on previous reports that estrogens exert a protective effect on the development of PAH through both nongenomic and genomic mechanisms. 28 Age/weight-matched wild-type (WT) mice served as experimental controls. All animals shared standard mouse chow and water and were maintained with an alternating 12-hour light/dark cycle under controlled temperature conditions. All animal studies were performed in accordance with the protocols approved by the Animal Care and Use Committee of Ruijin Hospital (Shanghai Jiaotong University School of Medicine).
HySu-Induced PAH Mouse Model
For the HySu group, 8-week-old male Lgmn −/− mice, Mac-Lgmn knockout mice, and age/weight-matched controls were exposed to chronic hypoxia (10% O 2 ) in a ventilated chamber for 3 weeks. SU5416, an inhibitor of the vascular endothelial growth factor The normoxia control group received only diluent. For groups treated with inhibitor RR-11a (Wuxi Apptech, Beijing, China), details can be referred to the previous study. 30 Briefly, RR-11a was freshly dissolved in PBS before administering it to mice. RR-11a was administered daily via intraperitoneal injection (20 mg/kg body weight) at the beginning of the third week until the end of the experiment. After 3 weeks, mice were euthanized by cervical dislocation, and tissues were subsequently harvested for further analyses.
TGF-β1 Activity Assay
TGF-β1 contents in lung tissues and cell supernatants including the total and active forms were analyzed using an ELISA kit (MB100B, R&D Systems, Minneapolis, MN). Briefly, the lung macrophages obtained from flow cytometric sorting were seeded in 24-well plates and divided into 4 groups. Two groups were derived from WT mice, and the other 2 groups were derived from Lgmn −/− mice. Macrophages were allowed to adhere overnight at 37°C and 5% CO 2 for 24 hours. Thereafter, the treatment group was administered 10 ng/mL of IL4 and IL13, as reported previously. 31 The control groups were only administered the diluent. Simultaneously, old media were replaced with 500 μL serum-free medium and cultured at 37°C and 5% CO 2 for 48 hours. The cell supernatant was harvested via centrifugation. As for lung tissues, after homogenization, the supernatant was harvested, and we also determined protein concentrations using a Pierce BCA Protein Assay Kit (Pierce, Rockford, IL). To detect active TGF-β1, it is necessary to activate the sample in advance with 1 N HCI and 1.2 N NaOH/0.5 mol/L HEPES. All samples, standards, and controls were assayed in duplicate. For MMP-2 inhibitor groups, MMP-2 inhibitor I (SC-204092, 5 μmol/L) (Santa Cruz Biotechnology, Santa Cruz, CA) was used to inhibit MMP-2 in macrophage culture medium 24 hours before assaying for TGF-β1 activity. The specific testing process is strictly in accordance with the manufacturer's instructions.
Statistical Analysis
All data are presented as the mean±SEM. χ 2 testing and Pearson correlation analysis were performed to assess discrete variables and correlations. For the detection of serum Lgmn contents within the population, we performed an unpaired Student t test based on the sample size of each group, which included 31 cases. The data passed the normality, and equal variance tests performed using the SPSS software (SPSS, Inc, Chicago, IL). Comparisons of 6 MWD, Lgmn serum levels, and left ventricular (LV) ejection fraction before and after PAH development were performed via the paired Student t test. Differences between 2 groups were assessed by the Mann-Whitney test, whereas the data obtained from multiple groups were compared using the KruskalWallis test, followed by Bonferroni post hoc testing. A P value lower than 0.05 was considered to mark a statistically significant difference. Statistical analyses were performed with GraphPad Prism 5.0 (Graph Pad Prism Software Inc., San Diego, CA) and SPSS 15.0 for Windows.
Results

Lgmn Is Upregulated in Lung Tissues of the HySuInduced PAH Mice and MCT-Induced PAH Rats
We initially detected Lgmn expression in lung tissues from HySu-treated mice. The results of Western blotting and quantitative polymerase chain reaction experiments showed that the Lgmn expression was significantly increased in lung tissues from HySu-induced PAH mice compared with normoxic control mice ( Figure 1A through 1C) . Besides, the HySu-exposed mice displayed a remarkable elevation in lung tissues Lgmn contents and serum Lgmn concentrations compared with normoxic controls, as determined in ELISA experiments ( Figure 1D and 1E). Interestingly, a clear positive correlation was found between the Lgmn serum concentration and the right ventricular systolic pressure (RVSP) and RV to LV+S weight (RV/(LV+S)) ratio ( Figure IA and IB in the online-only Data Supplement).
Moreover, we used an MCT-treated rat PAH model to evaluate Lgmn expression in lung tissues. Despite the different stimulus involved, whole-lung mRNA and protein levels were significantly higher in MCT-treated rats than in control rats ( Figure 1F through 1H) .
Deletion of Lgmn Systemically Inhibits the Development of PAH by Diminishing ECM Proteins Accumulation in PAs From HySu-Treated Mice
Next, we tested whether systemic disruption of Lgmn would attenuate the progression of PAH. After a 3-week exposure to HySu, the WT mice developed a significantly higher RVSP and RV/(LV+S) ratio than normoxic control mice ( Among the numerous pathological changes involved in pulmonary vascular remodeling, we were particularly interested in neomuscularization and fibrotic changes. By immunostaining for α-smooth muscle actin, a common marker reflecting the neomuscularization, no significant difference was observed in muscular PAs from Lgmn −/− mice and WT controls after HySu stress ( Figure 2C 
Pharmacological Blockade of Lgmn Protects Rats or Mice From MCT-or HySu-Induced PAH
The synthetic specific Lgmn inhibitor RR-11a can irreversibly inhibit Lgmn by forming a covalent bond with a cysteine residue. 30 ,32 Thus, we explored the therapeutic effect of RR-11a on pulmonary vascular remodeling in a rat model of PAHinduced via MCT and in a mouse model of PAH induced by HySu. Briefly, RR-11a was administered daily via intraperitoneal injection (20 mg/kg body weight) from the beginning of the third week until animals were euthanized ( Figure 4A ; Figure IVA in the online-only Data Supplement). As anticipated, the control groups showed significantly higher RVSP (35.43±1.631 mm Hg), RV/(LV+S) ratio (32.67±1.085%; Figure 4B and 4C), and thickness of the pulmonary vascular media wall ( Figure 4D and 4E), which demonstrated that the PAH model was established successfully. Similar to the genetic deficiency of Lgmn in mice, we observed that RR-11a protected against the increase in RVSP (26.43±1.360 mm Hg), RV/(LV+S) ratio (26.33±1.085%; Figure 4B and 4C), and the thickness of pulmonary vascular media wall ( Figure 4D through 4F) when compared with those not treated with RR-11a. Although no significant difference for α-smooth muscle actin + cells in muscular PAs from RR-11a and vehicle-treated rats ( Figure 4E ), collagen deposition in PAs ( Figure 4G ) was reduced in RR-11a-treated rats.
Consistently, we also observed the alleviated PAH phenotype including the reduced RVSP, RV/(LV+S) ratio as well as the thickness of the pulmonary vascular media wall ( Figure   Figure 1 . Lgmn (Legumain) expression was upregulated in pulmonary arterial hypertension (PAH) animals. A, Western blot analysis of Lgmn levels in lung tissues from wild-type (WT) mice exposed to normoxia or hypoxia plus SU5416 (HySu). B, Quantification of Lgmn bands in A was performed by densitometry and normalized to GAPDH. *P<0.05 vs normoxic controls; n=6 per group. C, Relative mRNA levels of Lgmn in lung tissues from WT mice exposed to normoxia or HySu environment. *P<0.05 vs normoxic controls; n=6-8 per group. D, Lgmn contents in lung tissues from WT mice after normoxia or HySu treatment. *P<0.05 vs normoxic controls; n=6-8 per group. E, Serum Lgmn contents measured in normoxia and HySu-induced WT mice. *P<0.05 vs normoxic controls; n=8 per group. F, Western blot analysis of Lgmn levels in lung tissues from rats treated with MCT (monocrotaline) or vehicle. G, Quantification of Lgmn bands in F was performed by densitometry and normalized to GAPDH. *P<0.05 vs vehicle controls; n=6 per group. H, Relative mRNA levels of Lgmn in lung tissues from rats treated with MCT or vehicle. *P<0.05 vs vehicle controls; n=6-8 per group.
IVB through IVF in the online-only Data Supplement) in the RR-11a-treated mice in comparison with the controls when exposed to the HySu. In addition to vascular morphological changes, the deposition of ECM proteins (COL1, FN, and TN-C) was significantly alleviated in PAs in mice administered with RR-11a (Figure VA through VD in the online-only Data Supplement). Collectively, these finds revealed that RR-11a could alleviate the development of PAH.
Lgmn Deficiency in Macrophage Ameliorates PAH in HySu-Induced PAH Mice
Consistent with previous studies showing that Lgmn is mainly expressed in macrophages, our immunofluorescence staining versus 32.25±0.8431%; P=0.0048; Figure 5C ). Moreover, the pulmonary vascular media wall thickness ( Figure 5D through 5F) and degree of muscularization ( Figure 5G ) also showed significant improvements. Furthermore, we measured ECM proteins (COL1, FN, and TN-C) deposition in PAs after 
Lgmn Promotes ECM Proteins Deposition in PAs Involved in Activating TGF-β1 Signaling
TGF-β1 signaling is a critical initiator and driver of ECM proteins deposition and fibrotic diseases. The signaling mediated by TGF-β isoforms is essential for PA remodeling in PAH. Based on these reputable reports, we tested the TGF-β1 contents in lung tissues from HySu-induced PAH mice. Consistent with changes in the deposition in ECM proteins, the contents of active TGF-β1 dramatically decreased in lung lysates from Lgmn F/F ×LysM Cre mice, albeit the total TGF-β1 levels were unchanged, as compared with Lgmn F/F counterparts when challenged with HySu ( Figure 7A ). Moreover, immunofluorescence staining revealed that the phosphorylation of SMAD2/3 (p-SMAD2/3) was suppressed more in PAs from Lgmn F/F ×LysM Cre mice than in Lgmn F/F mice, following exposure to HySu stress ( Figure 7B and 7C) . Similarly, the expression levels of downstream targets of p-SMAD2/3 (COL1 and FN) strikingly decreased in PAs from LgmnF/ F×LysMCre mice ( Figure 7D ; Figure IXA and IXB in the online-only Data Supplement).
Further, we validated the effect of Lgmn deficiency on TGF-β1 signaling in vitro by constructing a cell-based model. Because of a series of basic scientific studies demonstrated that administration of IL4 and IL13 (alone or in combination) could stimulate macrophages to produce and secrete Lgmn. 30, 31 Next, we isolated the pulmonary macrophages by flow cytometric sorting ( Figure 7E ). After incubation for 24 hours, ELISA analysis showed IL4/IL13-stimulated pulmonary macrophages significantly increased Lgmn expression as compared to the control groups ( Figure 7F ). To determine whether Lgmn deficiency in pulmonary macrophages can affect mPASMCs by altering TGF-β1 signaling, we incubated mPASMCs with conditioned medium from cultured macrophages stimulated with IL4/IL13. Not unexpectedly, immunofluorescence staining analysis revealed decreased SMAD2/3 phosphorylation ( Figure 7G ). In addition, the protein expression levels of downstream targets of TGF-β1 (COL1, FN, and TN-C) in mPASMCs cocultured with media obtained from Lgmn −/− macrophages stimulated with IL4/IL13 was markedly decreased (Figure 7H through 7J) .
To further investigate the effect of Lgmn deficiency on the TGF-β1 pathway in mPASMCs, we simultaneously extracted mouse peritoneal macrophages. Western blotting analysis revealed that the mPASMCs cocultured with media obtained from Lgmn −/− macrophages stimulated with IL4/IL13 displayed a significant reduction in SMAD2/3 phosphorylation and ECM protein levels ( Figure IXC through IXI in the online-only Data Supplement).
HySu-Induced Lgmn Expression Upregulates TGF-β1 Signaling in PASMCs by Activating MMP-2
As discussed above, Lgmn deficiency in macrophages can downregulate TGF-β1 signaling in mPASMCs. To our knowledge, TGF-β1 is synthesized and secreted into the ECM as latency-associated peptide, which binds to latent TGF-β1-binding proteins. The latent TGF-β1 complex is then activated by various proteases, including MMP-2/9, integrin, and Tsp-1 (thrombospondin-1). Indeed, Lgmn reportedly activates MMP-2 via proteolytic removal of an N-terminal propeptide.
Concurrent with previous studies, we observed that active MMP-2 was drastically reduced in the lung from Lgmn Figure 8F ). In addition, active TGF-β1 levels were significantly reduced in WT macrophages compared with the Lgmn −/− macrophages when treated with the MMP-2 inhibitor ( Figure 8G ). Real-time polymerase chain reaction data further confirmed the downstream targets of TGF-β1 (COL1, FN, and TN-C) in mPASMCs, which were significantly decreased after incubation with media from Lgmn −/− macrophages stimulated with IL4/IL13 compared with WT macrophage-derived media ( Figure 8H through 8K) . Collectively, these data indicate that Lgmn upregulates TGF-β1 signaling in PASMCs, at least in part, by activating extracellular MMP-2.
Lgmn Serum Levels Correlate With Disease Severity in Patients With iPAH
Basic demographic and iPAH-associated symptoms of 31 PAH patients and 31 control subjects are presented in the Table. Serum levels of Lgmn were strikingly higher in patients with iPAH than in controls ( Figure 9A ). Of note, a significantly positive correlation was observed between the serum Lgmn levels and mean pulmonary artery pressure in patients with iPAH (R 2 =0.4894, P<0.0001; Figure 9B ). Moreover, the pulmonary vascular resistance and pulmonary arterial systolic pressure also showed a strong association with serum Lgmn levels (R 2 =0.4496, P<0.0001; R 2 =0.4587, P<0.0001; Figure 9C and 9D) .
Clinically, the 6-minute walking distance and WHO functional class are recognized as 2 independent prognostic indicators that reflect the PAH severity. As expected, the serum Lgmn levels of patients who with a 6-minute walking distance <375 m and with WHO functional classes III and IV were markedly higher than those in patients with a 6-minute walking distance ≥375 m and with WHO functional classes I and II ( Figure 9E and 9F) .
After an average follow-up of 26 months (range, 16-40 months), unfortunately, only 12 patients survived; hence, we collected their sera to evaluate whether the serum Lgmn levels were altered after the patients received targeted drug therapy. All the 12 patients were treated with prostacyclin analogs, and 5 patients were taking a combination of phosphodiesterase-5 inhibitors. With regard to the response to medication, these patients showed a significant decrease in serum Lgmn concentrations compared with the early stage of disease, wherein they did not receive the targeted therapies ( Figure 9G ). In accordance with this result, these patients also displayed decreased WHO functional classifications (2.9, 95% CI, 2.372-3.428 to 1.9, 95% CI, 1.274-2.526, P=0.0011), increased 6-minute walking distance (435-354.8; P<0.001; Figure 9H and 9I), and improved LV ejection fraction ( Figure XIA in the onlineonly Data Supplement). Taken together, our data indicate that Lgmn may serve as a valuable biomarker for evaluating the efficiency of PAH treatment.
Discussion
In this study, we found that Lgmn expression was significantly upregulated in lung tissues from both HySu-induced PAH mice and MCT-treated PAH rats. Furthermore, by using pharmacological blockade and genetic-deletion approaches, we demonstrated that Lgmn was involved in PAH development. In addition, elevated Lgmn expression promoted HySuinduced TGF-β1 signaling and subsequent downstream target proteins by increasing extracellular MMP-2 activity. More interestingly, Lgmn-mediated MMP-2/TGF-β1 pathway activation was attributed to the direct interaction of Lgmn and MMP-2. Therefore, disruption of Lgmn potentially confers protection against PAH through inhibition of MMP-2/TGF-β1 signaling.
Lgmn is a newly discovered lysosomal cysteine protease belonging to the C13 family. Under physiological conditions, Lgmn expression was absent or present only at very low levels. However, under stress conditions such as hypoxia, starvation, and an acidic environment, Lgmn was upregulated and displayed significantly higher activity. 31, 33, 34 Coincidentally, our PAH model involves hypoxic stress and can thus provide a suitable milieu for Lgmn expression, and activation. 29 Extensive evidence showed that the other 3 closely related C13 family members (calpain, cathepsin, and caspase) all participated in PAH development. 35, 36 Briefly, calpain promoted PH by mediating collagen synthesis and TGF-β1-induced proliferation of PASMCs. 37, 38 Cathepsin D promoted cell proliferation and angiogenesis in PAs by degrading the matrix and releasing growth factors in PAH. 39 Caspase 3 led to apoptosis of pulmonary arterial endothelial cells and further impaired the endothelial function, thereby contributing to PAH progression. 40, 41 In this study, we found that Lgmn protein and mRNA were strikingly upregulated in lung tissues from HySu-exposed PAH mice and MCT-induced PAH rats. Furthermore, serum Lgmn levels were elevated in patients with iPAH, and a positive correlation was observed between serum Lgmn levels and disease severity. After treatment with a vasodilator, the Lgmn levels showed a clear trend towards abatement. No remarkable effect of Lgmn deletion was observed on PASMC proliferation in vivo and in vitro. Indeed, disruption or inhibition of Lgmn reduced the deposition of ECM proteins and the thickness of the smooth muscle layer in PAs. Finally, the RVSP and the thickness of the RV wall decreased in HySu-induced PAH models. These observations suggest that Lgmn upregulation in the lung tissues contributes to pulmonary vascular remodeling associated with PAH. Recent investigations indicate that Lgmn is primarily expressed in macrophages, 27, 42, 43 concurrent with the results of immunofluorescence staining in the present study, wherein Lgmn was located in macrophages. Hence, we continued to explore the effect of macrophages with knockedout Lgmn expression (Mac-Lgmn KO) on PAH development in mice. Previous studies have reported that LysM Cre , a recombinase we used to specifically knockout the Lgmn gene in macrophage, affects many other cell types, including neutrophils, neurons, and lung epithelial cells. 44, 45 Based on this, we examined the knockout efficiency of Lgmn in different cells to verify that Lgmn was only knockout in macrophages in the present study. Similar to the results observed after global Lgmn deletion, the macrophage-specific deficiency of Lgmn also yielded a phenotypic alleviation of PAH. Collectively, these observations suggest that Lgmn upregulation in lung tissues (especially in macrophages) contributed to pulmonary vascular remodeling in PAH.
Among all cytokines related to the pathogenesis of pulmonary vascular remodeling, TGF-β1 seems to be particularly important. 7, 46, 47 Previous reports demonstrated that TGF-β1 signaling exerts an integral role in iPAH patients and different PAH animal models. 48, 49 Inhibition of the TGF-β pathway can alleviate PAH in experimental PAH induced by exposure 6MWD indicates 6-minute walking distance; ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; CO, cardiac output; hs-CRP, high-sensitivity C-reactive protein; iPAH, idiopathic pulmonary arterial hypertension; IVST, interventricular septum thickness; LAD, left arterial diameter; LVEDD, left ventricular end-diastolic dimension; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic dimension; mPAP, mean pulmonary arterial pressure; PAH, pulmonary arterial hypertension; PASP, pulmonary artery systolic pressure; PCWP, pulmonary capillary wedge pressure; PVR; pulmonary vascular resistance; and WHO, World Health Organization. e143 to hypoxia, monocrotaline, or parasite Schistosoma mansoni. 37, 48, 50 TGF-β1 is synthesized and secreted into the ECM as an inactive precursor consisting of the latency-associated peptide and the mature TGF-β1 polypeptide. 51, 52 The latent TGF-β1 complex is then activated by several proteases, such as matrix MMP-2/9, integrin, and Tsp-1. [53] [54] [55] Furthermore, MMP-2 activity was significantly reduced in media obtained from Lgmn −/− macrophages stimulated with IL4/IL13, compared with the WT macrophages, which is in agreement with the alterations of active TGF-β1. Recent studies on Lgmn demonstrated that it could activate MMP-2 by proteolytic removal of an N-terminal propeptide. 25, [56] [57] [58] These observations indicate that Lgmn-mediated MMP-2 activation cleaves latency-associated peptide to active TGF-β1. In addition, elevated TGF-β1 signaling pathway occurred in the PAs from HySu-induced PAH mice, and PASMCs cocultured with media from macrophages stimulated with IL4/IL13. Interestingly, the loss of Lgmn suppressed activation of TGF-β1 signaling in PAs and PASMCs. A previous study reported that activated TGF-β1 signaling may also regulate MMP-2, enabling a positive feedback mechanism to accelerate PAH pathogenesis. 59 Similarly, MMP-2/TGF-β1 signaling and subsequent ECM proteins deposition play crucial roles in vascular restenosis and the stiffness of aged arteries. 38, 60, 61 The contents of active TGF-β1 markedly decreased in media obtained from WT IL4/ IL13-treated lung macrophages after exposure to the MMP-2-specific inhibitor, compared with the slight changes observed in the Lgmn −/− control group. These observations indicate that MMP-2 activation mediated by Lgmn promoted TGF-β1 signaling in HySu-induced PAH mice.
This study has a limitation. Owing to the lack of tissue and cell samples from PAH patients, current studies are focused only on animal models. Future studies on Lgmn in lung tissues from PAH patients are necessary. In summary, we showed .4587, P<0.0001) in patients with iPAH. n=31. E, The serum Lgmn levels in patients with 6-minute walking distance (6MWD) ≤375 m were higher than in those with 6MWD >375 m. *P<0.05 vs >375 m. n=15 or 16 per group. F, The serum Lgmn levels in patients with WHO functional classifications of III and IV were higher than in those with WHO functional classifications of I and II. *P<0.05 vs WHO I, II. N=15 or 16 per group. G, Serum Lgmn levels in patients with iPAH before and after treatment. *P<0.05 vs before; n=12 per group. H, WHO functional classification of patients with iPAH patients before and after. *P<0.05 vs before; n=12 per group. I, 6MWD of patients with iPAH before and after. *P<0.05 vs before; n=12 per group.
